PatientsVille.com LogoPatientsVille.com

Functional Dyspepsia | Rifaximin for Functional Dyspepsia

Functional Dyspepsia research study

What is the primary objective of this study?

Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people in the community. However, results of current pharmacological treatment on functional dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators test whether rifaximin is also effective in curing post-prandial distress symptoms related to dyspepsia.

Who is eligible to participate?

Inclusion Criteria: - Non-ulcer dyspeptic patients who fulfill post-prandial distress syndrome according to the Rome III Criteria - Active dyspeptic symptom - Normal upper endoscopy - Urea Breath Test -ve or Rapid urease test -ve - Not typical gastroesophageal reflux or biliary colic symptoms, but presence of infrequent acid reflux is allowed Exclusion Criteria: - No active dyspeptic symptom - Allergic to rifaximin - Recent antibiotics use in the past 8 wk - Recent PPI or H2RA in past 4 wk - On anti-coagulants, anti-convulsant or oral contraceptives - On NSAIDs, aspirin or Clopidogrel - Pregnancy or breast feeding - Previous gastric surgery

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Functional Dyspepsia

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:RifaximinRifaximin 400mg tid for 2 wk

Drug:PlaceboPlacebo for 2 week

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Rifaximin

Placebo

Study Status

Completed

Start Date: January 2013

Completed Date: May 2015

Phase: Phase 2/Phase 3

Type: Interventional

Design:

Primary Outcome: Adequate relief of dyspeptic symptoms at end of treatment

Secondary Outcome: Individual dyspeptic symptom scores

Study sponsors, principal investigator, and references

Principal Investigator: Wai Keung Leung, MD

Lead Sponsor: The University of Hong Kong

Collaborator:

More information:https://clinicaltrials.gov/show/NCT01643083

Discuss Dyspepsia